Questcor - 500 Beiträge pro Seite

[Brsenstorch]

Der neue Star am Biotechhimmel in Frankfurt schon + 6 %
heute.

[Brsenstorch]

Leute was ist los?
wo sind die Daytrader und Zocker hier.
mit der aktie kann mann täglich mal eben schnell so 10-20%
verdienen.
Abends limit 1,10 setzen , nachmittags zu 1,30 aussteigen
funktioniert bisher immer!

[DucklyUgly]

Hi Börsenstorch,

ich habe die Dinger mit 0,80 gekauft und letzten Montag zu 1,40 in edf verkauft.Die ideale Aktie für schnellen gewinn.

Ich bin schon wieder investiert!

Ich denke die nächsten 30% Gewinn sind realistisch bis zum Wochenende!!!!!

Gruß
Ugly Duckly

[puhvogel]

Star?

[Brsenstorch]

Der Star wird leuchten warts ab.
Kurzfristig 50 % Kursgewinn möglich.

[Tschey]

@ Brsenstorch:
Dass Du Dir nicht dämlich vorkommst, solche Scheiße zu posten...
"funktioniert bisher immer" Ha,ha,ha!
Sowohl in Frankfurt wie auch in Berlin erst seit Montag Umsatz bei der Aktie. Und das minimal(40.000€).
Schwankung gestern 1,08/1,20 heute 1,10/1,20.
Da es wohl nahezu unendlich viele Aktien gibt die im Tagesverlauf 10-20% schwanken, würde ich mir doch lieber eine suchen, wo man nicht gleich mit einer 100 € Order den Kurs manipuliert.
Der rasante Kursanstieg am Montag wird wohl auf den Insider-Aktienreport zurückzuführen sein, der die Aktie am Wochenende empfohlen hat,32%-Schwankung, bisher einmalig.
Daher auch der Kurseinbruch bei USA-Eröffnung.
Schön für Dich, falls Du wirklich am Montag zum Zuge
gekommen bist, aber gleich so einen großkotzigen Tip abzugeben,ts,ts,ts...

[pcopti]

News, habe ich gerade gefunden

Kann das jemand einschätzen ??

Quelle http://biz.yahoo.com/bw/010215/ca_questco.html


Thursday February 15, 8:11 am Eastern Time
Press Release
Questcor Partners Novel Antifungal Drug Research Technology with Tularik
HAYWARD, Calif.--(BW HealthWire)--Feb. 15, 2001--Questcor Pharmaceuticals, Inc. (AMEX:QSC - news) today announced that, in exchange for a cash payment and future potential milestone and royalty payments, it has exclusively licensed certain antifungal drug research technology to Tularik Inc., South San Francisco, California. In addition, Questcor has transferred to Tularik certain biological and chemical reagents to be used in the discovery and development of novel antifungal agents.

``We are very pleased to have licensed this technology to Tularik, a significant player in the discovery of new therapeutics which regulate gene expression`` commented Charles J. Casamento, Chairman, President and CEO of Questcor. ``We look forward to having Tularik develop and commercialize this novel antifungal technology.``

Upon closing the merger that created Questcor on November 17, 1999, the Company made a commitment to a strategy of development and marketing of late-stage specialty pharmaceutical products. As part of this transition, during 2000, Questcor licensed certain antibacterial drug discovery programs to Dainippon Pharmaceutical Co., Ltd., Osaka, Japan and certain antiviral drug discovery programs to Rigel, South San Francisco, California. These programs were based on Questcor`s novel approach to the development of new anti-infective products using translational control of gene expression.

``The Dainippon, Rigel and Tularik agreements allow us to share in the upside potential of products that are derived from this drug discovery pipeline while not incurring the development costs`` Mr. Casamento said. Each of the three agreements provides Questcor with potential milestone payments and royalties on future product sales. In addition, the Dainippon agreement provides Questcor with co-promotion rights in the US and Europe.

Questcor Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company whose focus is to serve the needs of the acute care and critical care hospital market. The Company`s strategy includes the acquisition and marketing of hospital pharmaceutical products, the generation of revenue streams from these products and the continued funding of late stage, acute care and critical care pharmaceutical research and development programs. As part of a strategy to develop its products globally, Questcor has entered into contractual relationships with CSC Pharmaceuticals HandelsGmbH of Vienna, Austria; Crinos Group of Como, Italy; Dainippon Pharmaceutical Co., Ltd., of Osaka, Japan; NutraMax Products, Inc. of Gloucester, MA; Rigel, Inc. of South San Francisco, CA; Shire Pharmaceuticals Group plc of Andover, UK; Laboratorios Silesia S.A. of Santiago, Chile and Ahn-Gook Pharmaceutical Co., Ltd, Seoul, Korea. Questcor was created as a result of the merger, on November 17, 1999, of RiboGene, Inc. and Cypros Pharmaceutical Corp.

Note: Except for the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties. Such statements are subject to certain factors, which may cause the Company`s results to differ. Factors that may cause such differences include, but are not limited to, the Company`s need for additional funding, uncertainties regarding the company`s intellectual property and other research, development, marketing and regulatory risks, and, the ability of the Company to implement its strategy and acquire products and, if acquired, to market them successfully as well as the risks discussed in Questcor`s transition report on Form 10-K for the fiscal year ended December 31, 1999, the Risk Factor section of Cypros` Registration Statement on form S-4 (No. 333-87611), and the Company`s quarterly reports on form 10-Q ended June 30, 2000 and September 30, 2000 respectively, and other documents filed with the Securities and Exchange Commission. The risk factors and other information contained in these documents should be considered in evaluating Questcor`s prospects and future financial performance.

[Brsenstorch]

Na hab ichs nicht gesagt, versteh zwar kein Englisch, aber hört sich doch sehr vielversprechend an.
ich sags euch das ding geht noch ab.
heute gute einstiegsgelegenheit.

gruß börsenstorch

[DucklyUgly]

Hey Tesche,

du hast doch überhaupt keine Ahnung vom Aktienmarkt.
Du bist nur die größte Niete, die ihr Geld am Sparbuch versauern läßt!

LOOSER

Der Tipp vom Börsenstorch ist gut und wird sich in den nächsten Tagen bewahrheiten!

[Tschey]

Hallo Ugly Duckling!
Ich habe nicht gesagt, dass mit der Aktie kein Geld zu verdienen ist, aber groß rumzuposaunen, man könne mit der Aktie "täglich" 10-20% machen,wenn erst seit 4 Tagen Umsatz in D vorhanden ist, von denen an 2 Tagen gerade 10% Schwankung im Tagesverlauf waren, muss man wohl zu dem Schluß kommen, daß da jemand Scheiße labert.
Ich habe den Artikel auch gelesen, in dem Questcor empfohlen wird. Hört sich auch ganz gut an, zumal die Vorsitzenden letztes Jahr selbst Aktien der eigenen Firma gekauft haben. Und bei so einem Winzwert (MK 22Mio $)sind auch einige 100% drin, keine Frage.
Aber wenn einer so rumtönt und definitiv falsche Angaben macht, darf ja wohl Kritik nicht fehlen, nachher glaubt das noch jemand mit dem Daytrading, wäre doch schade...

[puhvogel]

Wenn der CEO nicht wäre, könnte das eine prima Firma sein.

Ansonsten kann man nur auf einen Blitzschlag hoffen, oder fundamentalistische Terroristen, die zufällig gerade in Californien auf Geiselsuche sind.

[Brsenstorch]

und wieder 10 % Plus und das trotz allgemeiner Marktschwäche.
schnelle 10 % sind täglich fast immer möglich.
bin am freitag zu 1,05 rein und hab heute bei 1,20 verkauft.
setze nun ein abstauberlimit bei 1,03 .
zu zocken idealer wert!

gruß euer börsenstorch

[Steve de Ville]

Hi Börsenstorch

scheinst ja ein knüppelharter Daytrader mit Nerven aus Stahl
zu sein

bei 1,2 raus Klasse Umsatz 100 Stück

warte 100 x 0,15 Euro sind 15 Euro

ich bin schwer beeindruckt
weiter so


gruß Steve de Ville auf weitere große Geschäfte

[Brsenstorch]

he junge setz noch ein paar nullen hintendran und rechne nochmal wenn du es schaffst weiter wie bis hundert zu zählen.
gruß börsenstorch

[Steve de Ville]

tja was bleibt
ist ein mitleidiges lächeln

[ungünstig]

@ brsenstorch
schau mal in Deinen Briefkasten. Bitte!

[Powerbulls]

Manchmal stösst man echt auf Threads, die einen zum lachen bringen, und das hier ist so einer! Ich schmeiss mich echt vor Lachen ins Eck!!!

Powerbull

[JLL]

@Powerbull

dem ist nichts hinzuzufügen.


Am besten gefällt mir:

"Na hab ichs nicht gesagt, versteh zwar kein Englisch, aber hört sich doch sehr vielversprechend an."

Brsenstorch ist der legitime Nachfolger von Groucho Marx.

Gruß

JLL

[mn00]

Börsenfuzzi, deine Tips sind Gold wert.Warum postest du eigentlich jetzt nicht mehr?

[cheerdance]

Kann mir einer die Kursexplosion von Gestern erklären ? Gibt es neue Nachrichten ?

[puhvogel]

Und sie segeln weiter Richtung Untergang.

During the quarter ended September 30, 2001 product revenue increased 125% to $1,258,000 from $559,000 over the comparable quarter ended September 30, 2000.
Na gut, aber
General and administrative expense decreased 13% to $1,293,000 during the quarter ended September 30, 2001 from $1,490,000 in the comparable quarter ended September 30, 2000.
Na wow!
Für 1,5 Jahre reicht es noch

[koalabaer25]

Wieso Untergang? Die Aktie wird positiv gesehen. Es gibt eine sehr interessante Analyse über Questcor Pharmaceuticals. Werde diese heute abend bwz. nacht oder morgen reinstellen, wenn gewünscht.

Grüsse vom
Koalabaer25

[koalabaer25]

hier nun die Analyse:


LG ZANGANI, LLC REPORT Part 1 Nine Main Street· Flemington, NJ 08822 · 908-788-9660 · 908-788-4024 fax · E-mail:[e-mail] · Web site:http://www.zangani.com QUESTCOR PHARMACEUTICALS, INC. AMEX: QSC Fiscal Year: December 31 Approx. Shares Outstanding: 28.0 Million Approx. Float: 17.0 Million 52-Week Range: $0.38-$2.37 ♦Recent Bid: $1.35 ♦Market Cap: $23MM The Company Questcor Pharmaceuticals is an integrated specialty pharmaceutical company whose focus is to serve the emerging needs of the hospital environment. Through its current marketed products of Ethamolin®, Glofil™-125, Inulin, and Emitasol® (Pramidin® in Italy), Questcor presently addresses the respective hospital-based needs in esophageal variceal hemorrhage, accurate renal disease monitoring, wound management, and diabetic gastroparesis. In the near-term future, Questcor will introduce HP Acthar® Gel, a recently acquired marketed product. Some of the major shareholders in Questcor include Dainippon Pharmaceutical Company, Abbott Pharmaceuticals, Shire Pharmaceuticals, Sigma-Tau Pharmaceuticals, and Harvard University. A recent significant development for Questcor is the agreement signed on July 31, 2001, with Aventis Pharmaceuticals to acquire the worldwide rights to HP Acthar® Gel. HP Acthar® Gel is a corticotropin product that has been used as part of a special program administered by the National Organization for Rare Disorders (NORD) to treat seriously ill children with a seizure complex, known as West syndrome or infantile spasm, a potentially fatal disorder, and patients with multiple sclerosis who experience severe and painful episodes of “flare”. Approximately 1,600 patients have been treated with HP Acthar® Gel as part of the NORD program which restricted distribution of the product due to lack of availability. Due to the increased production and the increased availability, the product can now go into normal distribution and, therefore, an additional 5,000 patients suffering from autoimmune disorders may be helped by HP Acthar® Gel. The commercial impact from revenues and profits of HP Acthar® Gel should increase sales at Questcor to a level that is up dramatically from 2000 levels when product sales were less than $2 million.

LG ZANGANI, LLC REPORT Part 2 Another important recent development is a $6.5 million equity investment by Sigma-Tau, the leading research-based pharmaceutical company in Italy. In total, the Company has raised $7.7 million in 2001. With Sigma-Tau as a potential strategic partner, Questcor should have enough cash to the end of 2002, at which time they will be nearing the break even point. In addition to this relationship, Questcor has entered into 24 contractual relationships with public and private companies including: Ahn-#### Pharmaceuticals of Korea; Aventis Pharmaceuticals of Bridgewater, NJ; CSC Pharmaceuticals Handels GmbH of Vienna, Austria; Crinos Group of Como, Italy; Dainippon Pharmaceutical Co., Ltd., of Osaka, Japan; Rigel, Inc., of South San Francisco, CA; and Tularik, Inc. of South San Francisco, CA. The marketed pharmaceutical products available from Questcor include Glofil™-125, Inulin, Ethamolin®, and Pramidin® (marketed in Italy). Glofil™-125 and Inulin are used to measure kidney function. Kidney disease afflicts more than 2 million persons in the United States, where healthcare costs of over $12 billion are accrued annually. Because of the size of the diagnostic market for kidney disease, Questcor’s promotional efforts for Glofil™-125 are focused on establishing testing sites in all major markets in the US. Ethamolin® is used in the treatment of esophageal varices which are caused by end stage liver disease (hepatic cirrhosis). Hepatic cirrhosis results in 25,000 deaths annually and ranks ninth among the leading causes of death. It causes varices in the esophagus that may cause life threatening hemorrhage. Ethamolin® is the only agent approved by the FDA for the treatment of esophageal varices.


LG ZANGANI, LLC REPORT Part 3 Questcor has several ongoing development programs including Emitasol® Phase III trials and the development of cytoprotective drugs. Emitasol® is a product that may be used to treat stomach paralysis due to diabetic gastroparesis and to treat nausea and vomiting (delayed onset emesis) associated with cancer chemotherapy. Emitasol® is currently being developed in North America as well as in certain countries in Europe. It is on the market in Italy as Pramidin®. Questcor believes that Emitasol® when given intranasally may have advantages of ease of administration, earlier and faster onset of activity, and increased level of efficacy as compared to alternatives and cost effectiveness. Another promising medication is MigrastatTM, which is being developed to treat migraine headaches. It is currently in Phase II clinical trials. A medication that has the potential to treat congenital lactic acidosis, CeresineTM, is in late clinical trials. Congenital lactic aQuestcor has recently announced collaboration with Fabre Kramer Pharmaceuticals, Inc., of Houston, TX to jointly pursue the worldwide development and commercialization of HyponostatTM for insomnia and PanistatTM for panic disorders. The Letter of Understanding anticipates the formation of a joint venture, with funding of the joint venture by Fabre Kramer. Early Questcor clinical studies with HyponostatTM have shown, at reduced doses, a faster onset of sleep and a longer period of uninterrupted sleep than the currently available oral tablet formulations. The insomnia market in the US reached $1.5 billion in sales in 2000. PanistatTM will be developed as an acute intervention for individuals that suffer debilitating panic attacks. The National Institute of Mental Health reports that 2.4 million Americans experience panic attacks each year, and Questcor estimates that the panic disorder market in the US was in excess of $500 million in 2000.


LG ZANGANI, LLC REPORT Part 4 Products in the research and development stage include Glial Excitotoxin Release Inhibitors (GERIs). GERIs are a series of neuroprotective compounds that may prevent brain damage. Questcor is currently defining the chemical, toxicological and pharmacological effect of several GERI compounds and intends to file an IND for one of the compounds in 2002. There are three anti-infective drug discovery programs which have been partnered. Dainippon is developing Questcor’s anti-bacterial products, while Rigel and Tularik are developing the anti-viral and anti-fungal products respectively. Management Charles J. Casamento is Chairman of the Board, President and Chief Executive Officer of Questcor. Mr. Casamento formerly served as RiboGene’s President, Chief Executive Officer and Chairman of the Board since June 1993 (RiboGene and Cypros merged in November 1999 to form Questcor). Prior to joining RiboGene, he was co-founder, President and Chief Executive Office of Interneuron Pharmaceuticals. Prior to Interneuron he held various marketing, finance and business development positions with Genzyme, American Hospital Supply, Johnson & Johnson, Hoffmann LaRoche and Sandoz. Kenneth R. Greathouse joined Questcor in May 2000 as Vice President, Sales and Marketing. Prior to joining Questcor, he was Vice President of BoronLePore, a sales and marketing services outsourcing company located in Fair Lawn, New Jersey. Prior to BoronLePore, he was general manager for a division of Elan Pharmaceuticals and previously had held various marketing and sales positions at Athena Neurosciences and American Cyanamid. Scientific leadership includes neurologist Matt Kurth, M.D., chemist Mark Clement, Ph.D. and microbiologist Gary Witherell, Ph.D. SuL.G. ZANGANI, LLC Report Part 5 L.G Zangani, LLC provides financial public relations service to the Company. As such, L. G. Zangani, LLC and/or its officers, agents and employees, receives remuneration for public relations and/or other services performed for the Company. This remuneration may take the form of cash, capital stock in the Company, or warrants and/or options to purchase stock in the Company. The reader should verify all claims and do their own due diligence before investing in any securities mentioned. Investing in securities is speculative and carries a high degree of risk. The information found in this profile is protected by the copyright laws of the United States and may not be copied, or reproduced in any way without written consent. We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (“SEC”) at http://www.sec.gov and/or the National Association of Securities Dealers (“NASD”) at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer.cyberfr.htm. Readers can review all public filings by companies at the SEC’s EDGAR page. The NASD has published information on how to invest carefully at its web site.san Bonitz, PhD LG ZANGANI, LLCcidosis is a fatal disease occurring in children. There is currently no treatment for this disease.

L.G. ZANGANI, LLC Report Part 5 L.G Zangani, LLC provides financial public relations service to the Company. As such, L. G. Zangani, LLC and/or its officers, agents and employees, receives remuneration for public relations and/or other services performed for the Company. This remuneration may take the form of cash, capital stock in the Company, or warrants and/or options to purchase stock in the Company. The reader should verify all claims and do their own due diligence before investing in any securities mentioned. Investing in securities is speculative and carries a high degree of risk. The information found in this profile is protected by the copyright laws of the United States and may not be copied, or reproduced in any way without written consent. We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (“SEC”) at http://www.sec.gov and/or the National Association of Securities Dealers (“NASD”) at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer.cyberfr.htm. Readers can review all public filings by companies at the SEC’s EDGAR page. The NASD has published information on how to invest carefully at its web site.

Schönes Wochende
Koalabaer25

[puhvogel]

Ich habe doch die negativen Punkte aus der Einkommens-Bilanz schon zitiert.
Was die Pipeline angeht, so sah die vor 2 Jahren genauso aus, ohne das die sich ein Stückchen weiterbewegt hatte. Damals hätte ich QSC beinahe gekauft. Schau mal in die alten Jahresberichte von 2000 rein.
Der Casamento ist IMHO der schlechteste CEO, den ich mir so ausdenken kann und ich vermute mal, dass er den Laden nur deshalb am Leben erhält, um die Zeit bis zur Rente zu überbrücken.